New study confirms EpCAM as promising target for cancer immunotherapy

(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have shown that cancer immunotherapy targeting the tumor biomarker epithelial cell adhesion molecule (EpCAM) is safe and nontoxic in mice and can significantly delay tumor formation and growth.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news